Cancer Immunology, Immunotherapy View Homepage


Ontology type: schema:Periodical     


Journal Info

START YEAR

1982

PUBLISHER

Springer Berlin Heidelberg

LANGUAGE

en

HOMEPAGE

http://link.springer.com/journal/262

Recent publications latest 20 shown

  • 2019-04-10 Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma.
  • 2019-04-08 Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy.
  • 2019-04-06 T-cell recognition of non-mutated tumor antigens in healthy individuals: connecting endogenous immunity and tumor dormancy.
  • 2019-04-06 Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model.
  • 2019-04-05 Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.
  • 2019-04-05 Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.
  • 2019-04-03 Unlocking the therapeutic potential of primary tumor-draining lymph nodes.
  • 2019-04 Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice
  • 2019-04 MDSCs in infectious diseases: regulation, roles, and readjustment
  • 2019-04 Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates
  • 2019-04 MDSC and beyond: a symposium-in-writing on myeloid cells with immunoregulatory activity by members of the Mye-EUNITER network
  • 2019-03-09 Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial
  • 2019-03-07 HCT-116 colorectal cancer cells secrete chemokines which induce chemoattraction and intracellular calcium mobilization in NK92 cells
  • 2019-03 The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
  • 2019-03 The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice
  • 2019-03 Identification and characterization of an alternative cancer-derived PD-L1 splice variant
  • 2019-03 CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
  • 2019-02-26 Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model
  • 2019-02-26 First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
  • 2019-02-21 Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33160", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Oncology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B14000", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B11001", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Cancer Research", 
            "type": "DefinedTerm"
          }
        ], 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "0.99", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "1.899", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2017", 
            "ratingValue": "4.225", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2016", 
            "ratingValue": "4.711", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2016", 
            "ratingValue": "4.711", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2015", 
            "ratingValue": "4.846", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2015", 
            "ratingValue": "4.846", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2014", 
            "ratingValue": "3.941", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2014", 
            "ratingValue": "3.941", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2013", 
            "ratingValue": "3.943", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2013", 
            "ratingValue": "3.943", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2010", 
            "ratingValue": "4.293", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2010", 
            "ratingValue": "4.293", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "3.791", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "3.791", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2012", 
            "ratingValue": "3.637", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2012", 
            "ratingValue": "3.637", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2011", 
            "ratingValue": "3.701", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2011", 
            "ratingValue": "3.701", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2008", 
            "ratingValue": "3.804", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2008", 
            "ratingValue": "3.804", 
            "type": "Rating"
          }
        ], 
        "description": "

    Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology.\u00a0 The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others\u2019 results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms.

    In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:

    • \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u201cFocussed Research Reviews,\u201d published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.
    • \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u201cSymposia-in-Writing,\u201d which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.

    CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and\u00a0Sociedad Espa\u00f1ola de Inmunologia-Grupo Espa\u00f1ola de\u00a0InmunoTerapia\u00a0(SEI-GEIT).

    CIMT: http://www.cimt.eu/home

    CCIC: http://www.immunotherapycancer.ca/

    JACI: http://www.jaci.jp/eng/index.html

    NIBIT: http://www.nibit.org/index.php

    SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GK\u00a0\u00a0

    CITIM: http://www.canceritim.org", "editor": [ { "familyName": "Pawelec", "givenName": "Graham", "type": "Person" } ], "id": "sg:journal.1096240", "inLanguage": [ "en" ], "isAccessibleForFree": false, "issn": [ "0340-7004", "1432-0851" ], "license": "Hybrid (Open Choice)", "name": "Cancer Immunology, Immunotherapy", "productId": [ { "name": "dimensions_id", "type": "PropertyValue", "value": [ "96240" ] }, { "name": "springer_id", "type": "PropertyValue", "value": [ "262" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "sn 84010370" ] }, { "name": "wos_id", "type": "PropertyValue", "value": [ "0340-7004/CANCER IMMUNOLOGY IMMUNOTHERAPY" ] }, { "name": "scopus_id", "type": "PropertyValue", "value": [ "29152" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "8605732" ] }, { "name": "nsd_ids_id", "type": "PropertyValue", "value": [ "339854" ] }, { "name": "era_ids_id", "type": "PropertyValue", "value": [ "15463" ] } ], "publisher": { "name": "Springer Berlin Heidelberg", "type": "Organization" }, "publisherImprint": "Springer", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1096240" ], "sdDataset": "journals", "sdDatePublished": "2021-01-19T05:00", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///pack/app/journals_20190313_sn_only.jsonl", "startYear": "1982", "type": "Periodical", "url": "http://link.springer.com/journal/262" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1096240'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1096240'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1096240'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1096240'


     

    This table displays all metadata directly associated to this object as RDF triples.

    217 TRIPLES      21 PREDICATES      52 URIs      45 LITERALS      32 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1096240 schema:about sg:ontologies/product-market-codes/B11001
    2 sg:ontologies/product-market-codes/B14000
    3 sg:ontologies/product-market-codes/H33160
    4 schema:contentRating N1357f7ee908c4b9ba28e4d2cfc8f28dc
    5 N30cfa0e820dd49e1bdf4b8181328e1d4
    6 N38cd5b50719c4b2c8519b297997f2e05
    7 N4c2ac105af564af7beec37074981314d
    8 N56f6c30d393f4b1f8df3dda3fd239b76
    9 N5caecb7025964f61a573be653815d361
    10 N6fae8856086c4574b5938ae500268f01
    11 N75e4eff3eeed4567ae6a4ca9625bb89d
    12 N77d0d170bd654ebaacb8b0bc7201a228
    13 N7962619d0d764f1cb1158da1ce5eba0e
    14 N7c05ff9102bf43c9a0b9f161cdd3a1e9
    15 N80a04eff7d144f59932007d485f21257
    16 N8479efcb42b14b93b86568905ba46b88
    17 N85c503874bc2486f931a6a878f080ecc
    18 N93ff5b50e2a6416db3f2d5cfee2c4a11
    19 Naf77e6759c38432da91c770d3c47a5c1
    20 Nc2d5f99a5e2e430aaece8b71922ea987
    21 Ne70eafcc1ef3470b8e30398385956b24
    22 Nee983fa344ed4f0faf716bf1e83587fb
    23 Nf0137e8179024bd6b40215df1b70b542
    24 Nfa6a28687de94625bc5b76873ff99eb8
    25 schema:description <p>Since its inception in 1976, <i>Cancer Immunology, Immunotherapy</i> (CII) has reported significant advances in the field of tumor immunology.  The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms. </p><p>In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:</p><ul><li>         “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.</li><li>        “Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.</li></ul><p>CII is affiliated with the <i>Association for Cancer Immunotherapy (CIMT)</i>,<i> Canadian Cancer Immunotherapy Consortium (CCIC)</i>, <i>The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT</i>),<i> </i>and <i>Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT)</i>.</p><p>CIMT: http://www.cimt.eu/home</p><p>CCIC: http://www.immunotherapycancer.ca/</p><p>JACI: http://www.jaci.jp/eng/index.html</p><p>NIBIT: http://www.nibit.org/index.php</p><p>SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&amp;Upfqym5uom=GK  </p>CITIM: http://www.canceritim.org
    26 schema:editor Nf3f345380e1846f1a6c02965f7d851ec
    27 schema:inLanguage en
    28 schema:isAccessibleForFree false
    29 schema:issn 0340-7004
    30 1432-0851
    31 schema:license Hybrid (Open Choice)
    32 schema:name Cancer Immunology, Immunotherapy
    33 schema:productId N01942fab391f4851803f8a7c1d922016
    34 N0906e61911174983b228e33091777170
    35 N71baf000356b4a709a27527a6647dcdf
    36 N8852f3e8d5774e8597135120505acc80
    37 N96529d515461464cbd0e719a3fa5d542
    38 Nb58a881bd7b44cc7acafe87c001e4eef
    39 Nf18dd8adcb6b454b8c0791deee6511f2
    40 Nf4f027df8ee4410c89bf1fb8726fad60
    41 schema:publisher N8585b6fb268742cb9ef25d19f2f1edaf
    42 schema:publisherImprint Springer
    43 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1096240
    44 schema:sdDatePublished 2021-01-19T05:00
    45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    46 schema:sdPublisher N3ce6a695ad4e4725be6f25fc1bbd2e0b
    47 schema:startYear 1982
    48 schema:url http://link.springer.com/journal/262
    49 sgo:license sg:explorer/license/
    50 sgo:sdDataset journals
    51 rdf:type schema:Periodical
    52 N01942fab391f4851803f8a7c1d922016 schema:name scopus_id
    53 schema:value 29152
    54 rdf:type schema:PropertyValue
    55 N0906e61911174983b228e33091777170 schema:name nsd_ids_id
    56 schema:value 339854
    57 rdf:type schema:PropertyValue
    58 N0b472f34f62140578d07c7bba2b73545 rdf:first impact_factor_wos
    59 rdf:rest rdf:nil
    60 N1357f7ee908c4b9ba28e4d2cfc8f28dc schema:author N5b4023a20d1148ea898c8d91f348310a
    61 schema:dateCreated 2016
    62 schema:ratingValue 4.711
    63 rdf:type schema:Rating
    64 N2fba0a5bff8d42da80e499b17dda1c67 rdf:first impact_factor_wos
    65 rdf:rest rdf:nil
    66 N3024b02f5e254ac2ac7f7b7c729b0e35 rdf:first impact_factor_wos
    67 rdf:rest rdf:nil
    68 N30cfa0e820dd49e1bdf4b8181328e1d4 schema:author N49911cba04f64a5ca73bfd60403875c0
    69 schema:ratingValue 0.99
    70 rdf:type schema:Rating
    71 N34c929cecc4a48e39d632ede5932f201 rdf:first impact_factor_wos
    72 rdf:rest rdf:nil
    73 N353131ee2a7d4b9a95520423e31ce0b4 schema:familyName Pawelec
    74 schema:givenName Graham
    75 rdf:type schema:Person
    76 N38cd5b50719c4b2c8519b297997f2e05 schema:author N742b8dadf1f24abca4635edd291937c9
    77 schema:dateCreated 2011
    78 schema:ratingValue 3.701
    79 rdf:type schema:Rating
    80 N3ce6a695ad4e4725be6f25fc1bbd2e0b schema:name Springer Nature - SN SciGraph project
    81 rdf:type schema:Organization
    82 N43aa209dd75549fc993c6a1488ed0605 rdf:first impact_factor_wos
    83 rdf:rest rdf:nil
    84 N49911cba04f64a5ca73bfd60403875c0 rdf:first snip
    85 rdf:rest rdf:nil
    86 N4afdd8af46d14d91bf0c7cda0be54db9 rdf:first impact_factor_wos
    87 rdf:rest rdf:nil
    88 N4c2ac105af564af7beec37074981314d schema:author N5f92a104c8694e1e95ff9d77987fad05
    89 schema:dateCreated 2013
    90 schema:ratingValue 3.943
    91 rdf:type schema:Rating
    92 N4ef174e5ca544a3dadce49f8348956c8 rdf:first impact_factor_wos
    93 rdf:rest rdf:nil
    94 N550b9ec8ec634f0996631ebed09eeb8a rdf:first impact_factor_wos
    95 rdf:rest rdf:nil
    96 N56f6c30d393f4b1f8df3dda3fd239b76 schema:author N43aa209dd75549fc993c6a1488ed0605
    97 schema:dateCreated 2009
    98 schema:ratingValue 3.791
    99 rdf:type schema:Rating
    100 N5b4023a20d1148ea898c8d91f348310a rdf:first impact_factor_wos
    101 rdf:rest rdf:nil
    102 N5caecb7025964f61a573be653815d361 schema:author N88818b2ecf02408dad95dd6e04e0a042
    103 schema:dateCreated 2012
    104 schema:ratingValue 3.637
    105 rdf:type schema:Rating
    106 N5f92a104c8694e1e95ff9d77987fad05 rdf:first impact_factor_wos
    107 rdf:rest rdf:nil
    108 N6d5323b8f1a4490fa22c1af1dfdf7b98 rdf:first sjr
    109 rdf:rest rdf:nil
    110 N6fae8856086c4574b5938ae500268f01 schema:author Nd508389799204241a7b25e6e8971575e
    111 schema:dateCreated 2008
    112 schema:ratingValue 3.804
    113 rdf:type schema:Rating
    114 N71baf000356b4a709a27527a6647dcdf schema:name nlm_unique_id
    115 schema:value 8605732
    116 rdf:type schema:PropertyValue
    117 N742b8dadf1f24abca4635edd291937c9 rdf:first impact_factor_wos
    118 rdf:rest rdf:nil
    119 N75e4eff3eeed4567ae6a4ca9625bb89d schema:author N34c929cecc4a48e39d632ede5932f201
    120 schema:dateCreated 2010
    121 schema:ratingValue 4.293
    122 rdf:type schema:Rating
    123 N77d0d170bd654ebaacb8b0bc7201a228 schema:author N550b9ec8ec634f0996631ebed09eeb8a
    124 schema:dateCreated 2017
    125 schema:ratingValue 4.225
    126 rdf:type schema:Rating
    127 N7962619d0d764f1cb1158da1ce5eba0e schema:author N2fba0a5bff8d42da80e499b17dda1c67
    128 schema:dateCreated 2015
    129 schema:ratingValue 4.846
    130 rdf:type schema:Rating
    131 N7c05ff9102bf43c9a0b9f161cdd3a1e9 schema:author N4afdd8af46d14d91bf0c7cda0be54db9
    132 schema:dateCreated 2013
    133 schema:ratingValue 3.943
    134 rdf:type schema:Rating
    135 N7f9dfcfe58fa4ff387d7412f39f256e5 rdf:first impact_factor_wos
    136 rdf:rest rdf:nil
    137 N80a04eff7d144f59932007d485f21257 schema:author N7f9dfcfe58fa4ff387d7412f39f256e5
    138 schema:dateCreated 2014
    139 schema:ratingValue 3.941
    140 rdf:type schema:Rating
    141 N8479efcb42b14b93b86568905ba46b88 schema:author N3024b02f5e254ac2ac7f7b7c729b0e35
    142 schema:dateCreated 2012
    143 schema:ratingValue 3.637
    144 rdf:type schema:Rating
    145 N8585b6fb268742cb9ef25d19f2f1edaf schema:name Springer Berlin Heidelberg
    146 rdf:type schema:Organization
    147 N85c503874bc2486f931a6a878f080ecc schema:author N8907d49fcb5247418db741315b62acfc
    148 schema:dateCreated 2010
    149 schema:ratingValue 4.293
    150 rdf:type schema:Rating
    151 N8852f3e8d5774e8597135120505acc80 schema:name springer_id
    152 schema:value 262
    153 rdf:type schema:PropertyValue
    154 N88818b2ecf02408dad95dd6e04e0a042 rdf:first impact_factor_wos
    155 rdf:rest rdf:nil
    156 N8907d49fcb5247418db741315b62acfc rdf:first impact_factor_wos
    157 rdf:rest rdf:nil
    158 N93ff5b50e2a6416db3f2d5cfee2c4a11 schema:author N4ef174e5ca544a3dadce49f8348956c8
    159 schema:dateCreated 2009
    160 schema:ratingValue 3.791
    161 rdf:type schema:Rating
    162 N96529d515461464cbd0e719a3fa5d542 schema:name lccn_id
    163 schema:value sn 84010370
    164 rdf:type schema:PropertyValue
    165 N992c07eb86664dbf958e260e86d3244e rdf:first impact_factor_wos
    166 rdf:rest rdf:nil
    167 Naf566a92b0c64455ac7373f5772df1fc rdf:first impact_factor_wos
    168 rdf:rest rdf:nil
    169 Naf77e6759c38432da91c770d3c47a5c1 schema:author Naf566a92b0c64455ac7373f5772df1fc
    170 schema:dateCreated 2008
    171 schema:ratingValue 3.804
    172 rdf:type schema:Rating
    173 Nb58a881bd7b44cc7acafe87c001e4eef schema:name dimensions_id
    174 schema:value 96240
    175 rdf:type schema:PropertyValue
    176 Nc2d5f99a5e2e430aaece8b71922ea987 schema:author N6d5323b8f1a4490fa22c1af1dfdf7b98
    177 schema:ratingValue 1.899
    178 rdf:type schema:Rating
    179 Nd3d78697a7794ec792a85ec1f6609b55 rdf:first impact_factor_wos
    180 rdf:rest rdf:nil
    181 Nd508389799204241a7b25e6e8971575e rdf:first impact_factor_wos
    182 rdf:rest rdf:nil
    183 Ne70eafcc1ef3470b8e30398385956b24 schema:author Nd3d78697a7794ec792a85ec1f6609b55
    184 schema:dateCreated 2011
    185 schema:ratingValue 3.701
    186 rdf:type schema:Rating
    187 Ne74fea14146c4062bcf9bf932c379fcb rdf:first impact_factor_wos
    188 rdf:rest rdf:nil
    189 Nee983fa344ed4f0faf716bf1e83587fb schema:author N992c07eb86664dbf958e260e86d3244e
    190 schema:dateCreated 2014
    191 schema:ratingValue 3.941
    192 rdf:type schema:Rating
    193 Nf0137e8179024bd6b40215df1b70b542 schema:author Ne74fea14146c4062bcf9bf932c379fcb
    194 schema:dateCreated 2015
    195 schema:ratingValue 4.846
    196 rdf:type schema:Rating
    197 Nf18dd8adcb6b454b8c0791deee6511f2 schema:name era_ids_id
    198 schema:value 15463
    199 rdf:type schema:PropertyValue
    200 Nf3f345380e1846f1a6c02965f7d851ec rdf:first N353131ee2a7d4b9a95520423e31ce0b4
    201 rdf:rest rdf:nil
    202 Nf4f027df8ee4410c89bf1fb8726fad60 schema:name wos_id
    203 schema:value 0340-7004/CANCER IMMUNOLOGY IMMUNOTHERAPY
    204 rdf:type schema:PropertyValue
    205 Nfa6a28687de94625bc5b76873ff99eb8 schema:author N0b472f34f62140578d07c7bba2b73545
    206 schema:dateCreated 2016
    207 schema:ratingValue 4.711
    208 rdf:type schema:Rating
    209 sg:ontologies/product-market-codes/B11001 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    210 schema:name Cancer Research
    211 rdf:type schema:DefinedTerm
    212 sg:ontologies/product-market-codes/B14000 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    213 schema:name Immunology
    214 rdf:type schema:DefinedTerm
    215 sg:ontologies/product-market-codes/H33160 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    216 schema:name Oncology
    217 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...